Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
GTx (United States) · Brown University · +5 more institutions
Abstract
UNLABELLED: Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH. Weight reduction is typically recommended, but efficacy data are lacking. We performed a randomized controlled trial to examine the effects of lifestyle intervention using a combination of diet, exercise, and behavior modification, with a goal of 7% to 10% weight reduction, on clinical parameters of NASH. The primary outcome measure was the change in NASH histological activity score (NAS) after 48 weeks of intervention. Thirty-one overweight or obese individuals (body mass index [BMI], 25-40 kg/m(2)) with biopsy-proven NASH were…
Citation impact
- FWCI
- 28.40
- Percentile
- 100%
- References
- 45
Authors
8- KPKittichai PromratCorresponding
GTx (United States), Brown University, Providence VA Medical Center
- DEDavid E. Kleiner
United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute
- HMHeather M. Niemeier
University of Wisconsin–Whitewater, Brown University
- EHElizabeth H. Jackvony
Brown University
- MKMarie Kearns
Brown University
Topics & keywords
- Nonalcoholic steatohepatitis
- Randomized controlled trial
- Medicine
- Weight loss
- Steatohepatitis
- Internal medicine
- Gastroenterology
- Nonalcoholic fatty liver disease
- Good health and well-being